Strato

Strato DNS

Healthcare

Cedrik Britten

Board Member and Chairman of the Audit Committee

Mike Atieh

Chief Technology Officer

Steffen Walter

VP CMC

Ali Mohamed

US Site Head and VP of US Human Resources and Operations

Jessica Mosby

Associate Director

Amir Alpert, Ph.D

Senior Director Corporate Communications

Anja Heuer

Senior Director Clinical Operations

Anja Urban

Business Management

Ankita Patel

Associate Director, Companion Diagnostics

Anya Prokhorova

Friedrich Bohlen

Peter Chambre

Christof Hettich

Nancy Valente

Craig Slingluff

Harald Stock

Heather Mason

Christoph Huber

Carolin Mauch

Associate Director Financial Planning & Analysis

Martin Hofmann

Associate Director Immunology

Norbert Hilf

VP Translational Development

Martina Ott

Associate Director Target Validation

Arun Satelli

Arnd Christ

Chief Financial Officer

Toni Weinschenk

Sonja Dorner

Medical Companies With More Than 10 Employees (Top 10K)

Therapeutics Companies With Fewer Than 1000 Employees (Top 10K)

Europe, Middle East, and Africa (EMEA) Companies With More Than 10 Employees (Top 10K)

Europe, Middle East, and Africa (EMEA) Public Companies With More Than 100 Employees

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors.

The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors.

immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Post-IPO Equity - immatics biotechnologies

Moderna

Bristol-Myers Squibb

Perceptive Advisors

Celgene

Venture Round - immatics biotechnologies

Amgen

dievini Hopp Biotech Holding

Series E - immatics biotechnologies

Series D - immatics biotechnologies

Computer and Software Services and Scientific Services

Tübingen

Baden-Wurttemberg

Germany

Europe

immatics biotechnologies

Oligodendroglioma Treatment Market Size, Segmentation ...

Kidney Cancer Drugs Industry is Expected to Reach $8 Billion ...

Who are the leading innovators in SMAC mimetic peptides for ...

BioSpace Movers & Shakers, Sept. 18

United States

North America

Indonesia

Asia

Turkey

India

HTML5

Google Maps API

Microsoft Outlook

Google Fonts

Wordpress

Bootstrap

Vimeo

jQuery

Google Analytics

Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

Immatics N.V. Ordinary Shares

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 8, 2024 2:05 PM	58feb1cc
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 2:05 PM	e1bbc3b0
company summary	general
signals	general
crunchbase trigger	general	Oct 30, 2024 1:02 PM	653af438
crunchbase profile	general	Oct 30, 2024 1:37 PM	c723c7a1
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	c764ccb6
peers	general
news basic	general	Mar 8, 2024 2:05 PM	d84f230e
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:IMMATICS

Immatics

Last Close

7.58

22/11 21:00

Market Cap

922.56M

Beta: -

Volume Today

535.37K

Avg: -